Skip to main content
OKYO Pharma Ltd logo

OKYO Pharma Ltd — Investor Relations & Filings

Ticker · OKYO ISIN · US6793451088 US Manufacturing
Open in API
Filings indexed 274 across all filing types
Latest filing 2023-01-17 Regulatory Filings
Country US United States of America
Listing US OKYO

About OKYO Pharma Ltd

https://okyopharma.com/

OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for inflammatory eye diseases and chronic pain. The company's primary focus is on addressing significant unmet medical needs in neuropathic corneal pain (NCP) and dry eye disease (DED). Its lead product candidate, Urcosimod (OK-101), is a novel G protein-coupled receptor (GPCR) agonist that targets the chemerin receptor to produce anti-inflammatory and pain-reducing effects. OKYO is the first company to receive Investigational New Drug (IND) clearance from the FDA to clinically evaluate a drug specifically for NCP, a condition with no approved treatments. Urcosimod has also been granted Fast Track Designation by the FDA for the treatment of NCP.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter from OKYO Pharma Ltd. to the SEC requesting acceleration of the effective date for a Registration Statement on Form F-1/A under the Securities Act of 1933. It is a formal regulatory communication related to the registration process for securities, not a financial report or earnings release. The document is short (1226 characters) and serves as a regulatory filing to notify the SEC of the acceleration request. Therefore, it fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not contain financial statements or detailed report content.
2023-01-17 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form F-1/A. It requests acceleration of the effective date for the registration statement and discusses compliance with distribution and regulatory rules. The document is short (1887 characters) and is a formal communication related to the registration process of securities, not a financial report or detailed filing. It does not contain financial statements or detailed financial data. This type of document is best classified as a Regulatory Filing (RNS), as it is a regulatory communication related to the registration process and not a report itself.
2023-01-17 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC withdrawing a previously filed withdrawal request related to a Registration Statement on Form F-1/A. It is a short communication (886 characters) and does not contain any financial data, report content, or detailed disclosures. It is essentially a regulatory procedural notice. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2023-01-13 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from OKYO Pharma Ltd. to the SEC withdrawing a request for acceleration of the effective date of a Registration Statement on Form F-1/A. It is a regulatory communication related to the registration process for securities but does not contain financial statements, audit information, or detailed report content. The document is short (1154 characters) and is a formal regulatory filing or correspondence rather than a financial report or announcement of voting results, management changes, or other specific categories. Therefore, it fits best under Regulatory Filings (RNS).
2023-01-12 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from OKYO Pharma Ltd. to the SEC withdrawing a request for acceleration of the effective date of a registration statement on Form F-1/A. It is a regulatory communication related to a registration statement filing, not a financial report or detailed filing. The document is short (1146 characters) and serves as a formal notice rather than containing financial data or report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents.
2023-01-12 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form F-1/A. It requests acceleration of the effective date for the registration statement under Rule 461 of the Securities Act of 1933. The letter is from the underwriters and references the registration process for a securities offering. This is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to the registration and offering process. The document length is short and it is a formal communication to the SEC about the registration statement effectiveness, which fits the category of Regulatory Filings (RNS).
2023-01-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.